



February 19, 2020
Gene Techno Science Co., Ltd.
Code: 4584 (TSE Mothers)
Masaharu Tani, President & CEO

**End of Observation Period for the Last Patient in Phase III Clinical Trial
of Biosimilar Product for Ophthalmic Treatment in Japan
Developed with Senju Pharmaceutical Co., Ltd.**

Tokyo, February 19, 2020 – Gene Techno Science Co., Ltd. (“GTS”) announced that the observation period of the last patient in phase III clinical trial for our biosimilar product (development code: GBS-007) in the ophthalmology area has recently completed, which is being developed based on the joint business with Senju Pharmaceutical Co., Ltd. (“Senju”).

GTS and Senju continue to aim to obtain manufacturing and marketing approval for GBS-007, and actively promote the business development of this product not only in Japan, but in the larger global market, securing future revenue growth. Through the contributions to society by development of this product, we will accelerate to enhance our enterprise value and drive to realize GTS 3.0 at the earliest date.

About Gene Techno Science Co., Ltd.

GTS announced GTS 3.0 “Biotech Engineering Company, striving for value creation” a new business stage starting from this fiscal year, which targeted the pediatric disease in addition to the areas GTS has been engaged in such as the orphan disease and intractable disease. By leveraging the knowhow and expertise about biotechnology acquired in the past business activities, GTS is working on the development and provision of new medicines and therapeutic treatment for the purpose of achieving comprehensive healthcare solutions for the patients suffering from these diseases as well as families and caregivers.

Contact:

Gene Techno Science Co., Ltd.
Tel: +81-3-6222-9547 Mail: info@g-gts.com